Attribute level

Patients (n = 142)

Mean (SD)

Physicians (n = 127)

Mean (SD)

Increase in 3-year recurrence-free survival

4%

8%

12%

−43.0 (38)

8.9 (24)

34.1 (35)

−33.2 (43)

−2.3 (19)

35.5 (40)

10-year survival benefit in metastatic patients

No proven benefit

10% remain alive

21% remain alive

−77.8 (67)

6.8 (36)

71.0 (84)

−116.4 (78)

−4.1 (31)

120.5 (70)

Dosing regimen

Self-injection under skin 1 time per week for 5 years

−4.50 (43)

3.4 (25)

IV infusion at clinic 1 time every 3 week for 4 times then 1 time every 3 months for 3 years

15.5 (42)

−1.8 (28)

IV infusion at clinic 5 days a week for 1 month then self-injection under the skin 3 times per week for 1 year

−11.0 (40)

−1.6 (33)

Risk of moderate to severe fatigue

32%

60%

95%

45.8 (36)

12.4 (29)

−58.2 (30)

35.4 (38)

12.5 (25)

−47.9 (38)

Risk of moderate to severe diarrhea

1%

27%

41%

30.1 (31)

−3.2 (22)

−26.8 (30)

18.7 (32)

0.03 (30)

−18.8 (37)

Risk of moderate to severe depression

1%

40%

59%

39.4 (31)

−8.2 (21)

−31.2 (31)

28.7 (27)

−10.6 (22)

−18.2 (33)

Risk of hypophysitis

0%

5%

18%

9.1 (21)

11.2 (20)

−20.3 (25)

10.5 (26)

−1.7 (24)

−8.8 (32)

None

−90.7 (294)

−97.2 (212)